A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2006
12/14/2006	US20060280727 Dendritic cell isolation methods
12/14/2006	US20060280725 Compositions and methods of treating and diagnosing hepatoma
12/14/2006	US20060280722 Treatment of follicular lymphomas using inhibitors of the LT pathway
12/14/2006	US20060280684 Using lymphocyte gene expression profiles as diagnostic indicator of asthma, allergic and autoimmune disorders
12/14/2006	US20060280679 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/14/2006	DE202006007590U1 Use of agent that inhibits interaction between Sema7A and VLA-1 for treatment or prevention of cytokine-mediated diseases, e.g. osteoarthritis and arteriosclerosis
12/14/2006	CA2611861A1 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
12/14/2006	CA2611726A1 Pharmaceutical compositions containing sc(fv)2
12/14/2006	CA2611433A1 Novel analgesic treatment with prolonged effect using an anti-trka antibody
12/14/2006	CA2610987A1 Stabilizer for protein preparation comprising meglumine and use thereof
12/14/2006	CA2610771A1 Anti-trkb monoclonal antibodies and uses thereof
12/14/2006	CA2610685A1 Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
12/14/2006	CA2610596A1 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
12/14/2006	CA2609999A1 Stable and soluble antibodies inhibiting tnfalpha
12/14/2006	CA2609865A1 Modulation of cholesteryl ester transfer protein (cetp) activity
12/14/2006	CA2608818A1 Method of producing antibodies with modified fucosylation level
12/14/2006	CA2605583A1 Polyinosinic acid-polycytidylic acid-based adjuvant
12/13/2006	EP1731912A2 Peptide selection method
12/13/2006	EP1731612A1 Recombinant herpesvirus and utilization of the same
12/13/2006	EP1731611A2 Eimeria hydrophilic polypeptides as vaccines
12/13/2006	EP1731605A1 Cancer antigen peptides derived from wt1
12/13/2006	EP1731530A1 A kind of fusion protein, gene encoding it, expression method and use thereof
12/13/2006	EP1731168A1 Antibody drug
12/13/2006	EP1731167A1 Vaccine against hbv and hpv
12/13/2006	EP1731166A2 Streptococcus pneumoniae proteins and vaccines
12/13/2006	EP1731165A1 Allogenic placenta-lysates/BCG-vaccine
12/13/2006	EP1731162A2 Apparatus, method and compositions for the treatment of cancers by ultraphoresis
12/13/2006	EP1731161A1 Compositions for the treatment of diseases associated with elevated sphingolipid concentrations
12/13/2006	EP1730537A2 Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
12/13/2006	EP1730529A2 Methods of evaluating efficacy of an immune response by assessing alpha-1 integrin expression
12/13/2006	EP1730525A1 Immunoassays for everolimus
12/13/2006	EP1730520A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
12/13/2006	EP1730279A2 Epha4 as therapeutic target of prc and pdaca
12/13/2006	EP1730263A2 Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
12/13/2006	EP1730197A2 Methods for inducing autolysis in infectious bacteria
12/13/2006	EP1730196A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
12/13/2006	EP1730195A2 Estrogen receptors and methods of use
12/13/2006	EP1730194A2 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
12/13/2006	EP1730193A2 Monoclonal antibodies to gastrin hormone
12/13/2006	EP1730191A2 Immunoglobulins
12/13/2006	EP1730190A2 Inhibiting cav3 isoforms and the &25b splice varients for the diagnosis and treatment of cancer
12/13/2006	EP1730189A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
12/13/2006	EP1730185A1 Cancer associated antigens
12/13/2006	EP1730182A2 Chimeric vegf peptides
12/13/2006	EP1730180A1 Antifungal peptides
12/13/2006	EP1729821A2 Compositions and methods for topical application and transdermal delivery of botulinum toxins
12/13/2006	EP1729806A2 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
12/13/2006	EP1729805A2 Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
12/13/2006	EP1729803A2 Therapeutic use of anti-cs1 antibodies
12/13/2006	EP1729802A2 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
12/13/2006	EP1729801A2 Mutant viral nucleic acids and vaccine containing same
12/13/2006	EP1729800A2 Immunogenic compositions for chlamydia pneunomiae
12/13/2006	EP1729799A2 Chemically programmable immunity
12/13/2006	EP1729798A1 Antigen specific t cell therapy
12/13/2006	EP1729780A2 Methods for protein production
12/13/2006	EP1729750A2 Method for inhibiting tumor formation and growth
12/13/2006	EP1534836B1 Mutant forms of meningococcal adp-ribosylating toxin
12/13/2006	EP1482975B1 Prevention of tissue adhesion
12/13/2006	EP1290201B1 Recombinant subunit proteins from porcine parvovirus produced in plants
12/13/2006	EP1287133B1 Regulation of human dopamine-like g protein-coupled receptor
12/13/2006	EP1261712B1 Proteins named fctrx and nucleic acids encoding same
12/13/2006	EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
12/13/2006	EP1171605B1 Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
12/13/2006	EP1171156B1 Isolierte inslen, die insulin-produzierende zellen enthalten, beschichtete mit heparin
12/13/2006	EP1140156B1 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
12/13/2006	EP1126872B1 CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
12/13/2006	EP1123392B1 Prv-1 gene and the use thereof
12/13/2006	EP1121151B1 Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies
12/13/2006	EP1117803B1 Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
12/13/2006	EP1024836B1 Compositions for delivering genes to antigen presenting cells of the skin
12/13/2006	EP0991662B1 Chlamyidia trachomatis specific peptides and their use in diagnostic assays
12/13/2006	EP0927043B1 Compositions for gene transfer to the central nervous system
12/13/2006	EP0854885B1 Recombinant anti-cd4 antibodies for human therapy
12/13/2006	EP0809695B1 Transcription factor - e2f-5
12/13/2006	EP0760602B1 Use of fas ligand to suppress lymphocyte-mediated immune responses
12/13/2006	EP0678035B9 Vaccine preparations
12/13/2006	EP0651805B1 Method of intracellular binding of target molecules
12/13/2006	CN1878867A Recombinant peptide vector comprising the gene for treatment for autoimmune diseases
12/13/2006	CN1878793A Monoclonal antibodies against HMGB1
12/13/2006	CN1878568A Enhanced B cell cytotoxicity of CDIM binding antibody
12/13/2006	CN1878567A Improvements in vaccination
12/13/2006	CN1878566A Multi-antigen vectors of melanoma
12/13/2006	CN1878562A Antybody therapy
12/13/2006	CN1876826A Production and amplification method for recombinant protein medicine by ammonia salt forced fermentation
12/13/2006	CN1876683A Human antibodies that bind human TNFalpha
12/13/2006	CN1876679A Compounds from moraxella catarrhalis
12/13/2006	CN1876181A Weak toxicity united vaccine formulation for canidae animal important disease series and preparation process
12/13/2006	CN1876180A Use of protein TolC in preparing immunological formulation and vaccine
12/13/2006	CN1876179A Use of protein YaeT in preparing immunological formulation and vaccine
12/13/2006	CN1289682C Expression of genes in modified vaccinia virus ankara by using the cowpox ATI promoter
12/13/2006	CN1289674C DNA vaccine-PCV
12/13/2006	CN1289671C Antibody molecules having specificity for human tumor necrosis factory alpha, and use thereof
12/13/2006	CN1289663C Method for the recovery and purification of poxviruses from infected cells
12/13/2006	CN1289660C Method of preparing undifferentiated cell
12/13/2006	CN1289147C Process for preparing antitoxin
12/13/2006	CN1289146C Nucleic acid vaccine for preventing and treating hepatitis B virus inflammation and its preparation
12/13/2006	CN1289073C Hair growth stimulant
12/13/2006	CN1289065C Vaccine containing saponin and sterol
12/13/2006	CN1289063C Immune modulation device for use in animals
12/13/2006	CN1289061C Medicine for preventing and treating bromidrosis

1 ... 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 ... 1823